Additionally, the 36-month beta value for ALT is 1.14. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for ALT is 76.21M and currently, short sellers hold a 28.63% ratio of that float. The average trading volume of ALT on April 23, 2025 was 2.50M shares.
ALT) stock’s latest price update
The stock price of Altimmune Inc (NASDAQ: ALT) has jumped by 3.54 compared to previous close of 4.85. Despite this, the company has seen a gain of 10.85% in its stock price over the last five trading days. accessnewswire.com reported 2025-04-10 that ALT5 joins the Securities Industry and Financial Markets Association (SIFMA) LAS VEGAS, NV / ACCESS Newswire / April 10, 2025 / ALT5 Sigma Corporation (NASDAQ:ALTS)(FRA:5AR1), a fintech specializing in turnkey, crypto-related solutions that support account opening, compliance, wealth management, payments, tokenization, and custody, today announced the launch of ALT5 Prime as the engine behind its new ALT5 Crypto-as-a-Service (ALTCaaS) offering. Designed for wealth management, retail and institutional broker-dealers, banks, and credit unions, ALTCaaS provides a turnkey, customizable, fully compliant solution to enter the digital asset space quickly and securely.
ALT’s Market Performance
ALT’s stock has risen by 10.85% in the past week, with a monthly drop of -17.00% and a quarterly drop of -27.64%. The volatility ratio for the week is 6.65% while the volatility levels for the last 30 days are 8.22% for Altimmune Inc The simple moving average for the past 20 days is 8.07% for ALT’s stock, with a -25.43% simple moving average for the past 200 days.
Analysts’ Opinion of ALT
Stifel, on the other hand, stated in their research note that they expect to see ALT reach a price target of $18. The rating they have provided for ALT stocks is “Buy” according to the report published on January 08th, 2025.
UBS gave a rating of “Buy” to ALT, setting the target price at $26 in the report published on November 12th of the previous year.
ALT Trading at -7.87% from the 50-Day Moving Average
After a stumble in the market that brought ALT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.00% of loss for the given period.
Volatility was left at 8.22%, however, over the last 30 days, the volatility rate increased by 6.65%, as shares sank -13.16% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.62% lower at present.
During the last 5 trading sessions, ALT rose by +12.91%, which changed the moving average for the period of 200-days by -22.73% in comparison to the 20-day moving average, which settled at $4.65. In addition, Altimmune Inc saw -30.35% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALT starting from Sohn Catherine A., who purchase 1,000 shares at the price of $5.78 back on Mar 17 ’25. After this action, Sohn Catherine A. now owns 1,000 shares of Altimmune Inc, valued at $5,784 using the latest closing price.
WEAVER GREGORY L, the Chief Financial Officer of Altimmune Inc, purchase 10,000 shares at $5.20 during a trade that took place back on Mar 13 ’25, which means that WEAVER GREGORY L is holding 10,000 shares at $51,996 based on the most recent closing price.
Stock Fundamentals for ALT
Current profitability levels for the company are sitting at:
- -5158.6 for the present operating margin
- -7.4 for the gross margin
The net margin for Altimmune Inc stands at -4752.95. The total capital return value is set at -0.8. Equity return is now at value -59.86, with -54.33 for asset returns.
Based on Altimmune Inc (ALT), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -47.5. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -11463.56.
Currently, EBITDA for the company is -94.81 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of 17433.4. The receivables turnover for the company is 0.01for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.10.
Conclusion
In conclusion, Altimmune Inc (ALT) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
